 |
|
|
| |
A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Week 48 Efficacy and Safety Results
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Henry LY Chan1, Scott Fung2, Wai Kay Seto3, Wan-Long Chuang4, Chi-Yi Chen5, Hyung Joon Kim6, Aric Josun Hui7, Harry LA Janssen8,9, Abhijit Chowdhury10, Tak Yin Owen Tsang11, Rajiv Mehta12, Edward Gane13, John F Flaherty14, Benedetta Massetto14, Kathryn M Kitrinos14, Phillip Dinh14, G Mani Subramanian14, John G McHutchison14, Young-Suk Lim15, Subrat K Acharya16, Kosh Agarwal17
1The Chinese University of Hong Kong, China; 2Toronto General Hospital, Toronto, Ontario, Canada; 3Queen Mary Hospital, Hong Kong; 4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 5Chiayi Christian Hospital, Chiayi, Taiwan; 6Chung-Ang University Hospital, Seoul, South Korea; 7Alice Ho Miu Ling Nethersole Hospital, Hong Kong; 8Toronto Western Hospital, Toronto, Ontario, Canada; 9Erasmus Medical Center, Rotterdam, Netherlands; 10Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India; 11Princess Margaret Hospital, Hong Kong; 12Surat Institute of Medical Sciences, Surat, Gujarat, India; 13Auckland Clinical Studies, Auckland, New Zealand; 14Gilead Sciences, Inc., Foster City, CA, USA; 15Asan Medical Center, Seoul, South Korea; 16All India Institute of Medical Sciences Delhi, New Delhi, India; 17King's College Hospital, London, UK
|
| |
|
|
|
|
|
